Default company panoramic image
Cd0bfa7e 842b 4405 93b9 81d7c6dd2add


BioSavita is accelerating the development of biosimilar antibodies and offers a new expression system for better and faster production.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Plymouth, MI, USA
  • Currency USD
  • Employees 6
  • Website

Company Summary

BioSavita licenses a yeast based antibody expression platform to biopharma for development and production of biosimilar cancer antibodies. Large pharma uses the platform as well as the company has expressed anti-cancer molecules. One program, anti-CD52 which is Campath offers a treatment for multiple sclerosis and leukemia. The company has 5 licensees and a pipeline of internally developed drugs. Strong management team and business model.


  • Default avatar
    James Kuo

    Dr Kuo, MD, MBA, has over 20 years of experience in the life science industry as a venture capitalist, pharmaceutical business development executive and senior manager of private and publicly-traded biotech companies. Previously, Dr. Kuo served as Chairman and Chief Executive Officer of Adeona Pharmaceuticals.

  • Default avatar
    Nalini Motwani

    Dr. Motwani has over 25 years of experience in research and business development and technology licensing in biotechnology. She has been successful in recruiting the current technical and management team and scientific advisors. Under her leadership, the predecessor company, ApoLife, has been successful in receiving NIH grant awards, developing technology and negotiating licensing deals which generate current revenues. She focuses on technolog

  • Default avatar
    Martina Molsbergen
    VP Business Development

    Formerly VP of Business development at Crucell NV and VP Business Development at BioWA, two antibody platform companies. She has successfully negotiated licensing deals of over $3.6B for biopharma companies with antibody platforms and is securing new licensing partners for BioSavita.

  • Default avatar
    David Bramhill
    VP Strategic Partners

    David has 20 years of experience in R&D, business development and licensing in biotech. He was Dir of Licensing at RCT from 2007-11 where he managed out-licensing platform technologies, including 50 licensees of Pichia yeast expression technology. Prior to this, David was associate director at Merck Research Labs for 14 years where he led evaluation of all technology platforms required for discovery and development of therapeutic mAbs.


  • Default avatar
    Dennis Loy
    Default avatar
    Gary Hessenaur

Previous Investors

  • Default avatar
    MIchigan Life Sciences Corridor
    Default avatar
    First Step Fund